The phase III REZILIENT3 trial met its primary endpoint, with the investigational agent zipalertinib plus chemotherapy significantly improving PFS over chemotherapy alone for first-line advanced NSCLC with EGFR exon 20 insertion mutations. Conversely, the phase III SKYSCRAPER-03 trial showed no PFS benefit from adding the investigational anti-TIGIT antibody tiragolumab to atezolizumab versus standard durvalumab for patients with unresectable NSCLC post-chemoradiation. Additionally, new biomarker analyses from the CheckMate 77T trial were published, detailing correlative work including ctDNA clearance and post-surgical MRD.
“Press release: Phase III REZILIENT3 trial meets its primary endpoint. Adding zipalertinib to first line chemotherapy for advanced NSCLC with an EGFR exon 20 insertion mutation significantly improved PFS over chemo alone.”
— @StephenVLiu · REZILIENT3 trial · View post ↗
“This is the level of correlative work every phase 3 should aim for: ctDNA clearance, post-surgical MRD, WES, PROs, all reported together.”
— @YGaritaonaindia · CheckMate 77T biomarker analysis · View post ↗📌 Amplified by @KolPulseAI
“Another phase III trial fails to improve outcomes over the PACIFIC regimen for stage III NSCLC. This time SKYSCRAPER-03, which compared post CRT Tiragolumab + Atezolizumab vs Durvalumab.”
— @DrewMoghanaki · SKYSCRAPER-03 trial · View post ↗A post-hoc analysis of the EN-SEMBLE study in 26 patients with HER2-positive metastatic breast cancer rechallenged with T-DXd showed a 27% ORR and 6.5-month median real-world PFS. Separately, an exploratory analysis of CAPItello-291 suggests PTEN IHC may identify patients with HR+/HER2- advanced breast cancer who benefit from capivasertib, even without NGS-detected alterations. In first-line advanced TNBC, investigational ivonescimab plus a taxane demonstrated an 80% ORR in a small phase 2 study.
“ORR 27%, median rwPFS 6.5 mo, OS 14.2 mo. Longer rwPFS in those who had stopped T-DXd for reasons other than progression. No ILD on rechallenge.”
— @kazuki_nozawa · T-DXd Rechallenge · View post ↗📌 Amplified by @KolPulseAI
“First-line ivonescimab+taxane in advanced TNBC (n=36): ORR 80%, mPFS 15.2 mo. In CPS<10 disease, ORR was 79.3% and mPFS 13 mo—the key signal.”
— @dr_yakupergun · Ivonescimab in TNBC · View post ↗📌 Amplified by @KolPulseAI
“Most interestingly, among PTEN-deficient tumors without PIK3CA/AKT1/PTEN alterations detected by NGS: mPFS 16.2 vs 4.6 mo HR 0.43 (95% CI 0.15–1.05)”
— @DrRishabhOnco · PTEN IHC for Capivasertib · View post ↗The phase III TNTCRT trial in high-risk locally advanced rectal cancer (LARC) showed that adding CAPOX before, during, and after long-course radiation improved 3-year disease-free survival to 74.8% vs 66.0% for conventional chemoradiation followed by surgery and adjuvant chemo. In hepatocellular carcinoma (HCC), the phase III TORCH trial found that TACE plus thermal ablation significantly improved median OS to 88.6 months versus 35.1 months for TACE alone in unresectable, liver-confined disease. Additionally, Depth of Response (DpR) is being discussed as a novel efficacy endpoint in HCC, with data from trials like IMbrave150 and HIMALAYA showing its correlation with overall survival.
“👉 Depth of response (#DpR) shows strong correlation with OS across multiple phase 3 ICI-based trials”
— @hongjaechon · HCC Efficacy Endpoints · View post ↗
“The control arm is not how we treat high-risk rectal cancer in the US. We already know TNT is better than CRT → surgery → adjuvant chemotherapy based on OPRA's modern benchmark.”
— @GIMedOnc · TNTCRT Trial Comparator · View post ↗
“TORCH is a little tricky to interpret because it essentially compares TACE deliberately left incomplete with TACE followed by ablation. In some ways, that feels more like “inadequate local therapy” vs “adequate local therapy” than a clean test of what TACE itself adds.”
— @jryckman3 · TORCH Trial Interpretation · View post ↗📌 Amplified by @KolPulseAI
“💡 Current surveillance works—but misses a relevant share of cancers.”
— @DraMartinezLago · Lynch Syndrome Surveillance · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
The LITESPARK-011 trial, published in The Lancet, showed the investigational combination of belzutifan plus lenvatinib improved median PFS to 14.8 months versus 10.7 months for cabozantinib (HR 0.70) in advanced ccRCC after anti-PD-(L)1 therapy, with no significant difference in OS at interim analysis. In prostate cancer, a new analysis from the PROpel trial highlighted the greatest benefit from olaparib plus abiraterone in mCRPC patients with BRCA2 mutations. Additionally, the largest real-world dataset on Lu-PSMA-617 (n=3,709) showed a median imaging PFS of 7.6 months, similar to the VISION trial, in an older, more heavily pretreated population.
“Median PFS: 14.8 vs 10.7 months (HR 0.70). OS not significantly different at interim (HR 0.85).”
— @drenriquegrande · LITESPARK-011 in ccRCC · View post ↗📌 Amplified by @KolPulseAI
“New insights from #PROpel: olaparib + abiraterone showed the greatest benefit in #mCRPC with #BRCA2 mutations, highlighting the importance of genomic testing to guide treatment decisions and advance precision oncology.”
— @g_procopio_ · PROpel subgroup analysis · View post ↗
“Median imaging PFS 7.6 months vs 8.7 in VISION, in older and more heavily pretreated men”
— @katy_beckermann · Real-world Lu-PSMA-617 data · View post ↗
“Our original article — higher LAG-3 expression in RCC was associated with a distinct immune-rich TME and improved rwORR to 1st line IO, serving as a potential biomarker of early IO response.”
— @HersheyDudipala · LAG-3 as RCC biomarker · View post ↗On August 13, 2026 the U.S. FDA granted accelerated approval to the CELMoD agent iberdomide (brand name Zenbexus, Bristol Myers Squibb) in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for adult patients with relapsed or refractory multiple myeloma after at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. The FDA approval is based on the Phase 3 EXCALIBER-RRMM trial, which showed the iberdomide regimen achieved a 41% MRD-negative complete response rate versus 21% for the control arm (daratumumab, bortezomib, dexamethasone); PFS data are still immature. Commentary also highlighted a study of an investigational bispecific BCMA/GPRC5D CAR-T for extramedullary myeloma, which showed a 97% ORR but a median PFS of only 5.8 months.
“Iberdomide (first CELMoD) now @US_FDA ✅ based off EXCALIBER-RRMM in 2L and beyond for R/R #MultipleMyeloma. IberDd: - Improved MRD (41% vs. 21%) - PFS still immature - AEs: Cytopenias and Infections ”
— @OncBrothers · Iberdomide FDA approval · View post ↗📌 Amplified by @KolPulseAI
“🛑High % of neutropenia: 90% (any grade); Grade 3: 31%, Grade 4: 53%”
— @HadidiSamer · Iberdomide safety profile · View post ↗📌 Amplified by @KolPulseAI
“Bispecific BCMA/GPRC5D CAR T for extramedullary myeloma (Zhou et al.) hits striking early efficacy: 97% ORR, 43% stringent CR, 100% MRD-negativity in responders. But durability lags: median PFS just 5.8mo, with EMD-site relapse the main driver.”
— @hhashmi87 · Bispecific CAR-T durability · View post ↗📌 Amplified by @KolPulseAI
“🚨 REMS program won't go live until September 14th at the earliest, so not possible to prescribe commercial iberdomide still after then.”
— @RahulBanerjeeMD · Iberdomide access · View post ↗📌 Amplified by @KolPulseAI
A new study highlighted by Haematologica examined the incidence and features of subsequent myeloid neoplasms in patients with T-follicular helper cell non-Hodgkin lymphoma. Other commentary focused on therapy-related hematologic malignancies, noting that the IDH2 R140Q group is characterized by DNA hypermethylation and enrichment for focal IKZF1 deletions, and that IMiD discontinuation may lead to regression of secondary leukemia in some cases.
“How often do patients with T-follicular helper cell non-Hodgkin lymphoma develop a subsequent myeloid neoplasm?”
— @Haematologica · Secondary Myeloid Neoplasms · View post ↗
“The IDH2 R140Q group is characterized by DNA hypermethylation not dissimilar to IDH2-mutant AML.”
— @BenDiamondMD · Therapy-Related Malignancies · View post ↗“In some cases, discontinuation of the IMiD may lead to regression of the secondary leukemia.”
— @BenDiamondMD · Therapy-Related Malignancies · View post ↗